Monograph Details
|
|
Immune System
> Immunization
|
|
PEDVAXHIB |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Hib (PRP-OMP). |
| Generic Name |
|
Haemophilus b conjugate 7.5micrograms (meningococcal protein conjugate 250micrograms); per 0.5mL; IM inj. |
| Indications |
|
Immunization of children against H. influenzae type b. |
| Children |
|
<2 months: not recommended. 2 and 4 months: 0.5mL lM. Children vaccinated (with 2 dose regimen) before 12 months should receive booster at 12 months (but not <2 months after previous shot). Previously unvaccinated children, 15–71 months: 0.5mL lM once. |
| Contraindications |
|
Aluminum allergy. |
| Precautions |
|
Immunodeficiency. Delay administration in febrile or active infection. Have epinephrine inj (1:1000) available. Protection begins several days after injection. Pregnancy (Cat. C): not recommended. |
| Adverse Reactions |
|
Local reactions, fever. |
| How Supplied |
|
Single-dose vials (w. diluent)—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
